Clinical and Practice Updates for Age-Related Macular Degeneration and Diabetic Macular Edema

This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.

Program Description

For patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), treatment has been proven with intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies. In 2019, nearly 7 million anti-VEGF injections were performed in the United States for patients with these conditions, contributing to significant burden for patients, caregivers, and the health care system. Specialty and managed care pharmacists can make important interventions for patients with nAMD and DME by incorporating new and emerging treatment options into formularies. This activity will review considerations for current treatment options, emerging dual-targeted therapy with the angiopoietin (Ang) pathway, and the potential role of new medication delivery systems for patients with nAMD or DME. The pharmacist’s role in combating nonadherence and reducing health care resource utilization for patients with nAMD and DME will also be examined.

Target audience: Specialty pharmacists and managed care pharmacists

Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the current treatment options for neovascular age-related macular degeneration and diabetic macular edema
• Analyze the latest efficacy and safety data for emerging therapies and treatment approaches for neovascular age-related macular degeneration and diabetic macular edema
• Demonstrate the role of specialty pharmacists and managed care professionals in the management of neovascular age-related macular degeneration and diabetic macular edema

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-239-H01-P. The activity is available for CE credit through May 10, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Alan Pannier, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose.

Joshua Mali, MD, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support – Alimera Sciences, Allergan, Chengdu Kanghong Biotechnology, Regeneron, Santen, Notal Vision

• Consultant – Alimera Sciences, Allergan, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron, Sun Pharmaceuticals

• Speakers Bureau – Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Sun Pharmaceuticals

• Stock Equity/Shareholder – AbbVie, Regeneron

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Michelle C. Carlson; PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms